Kinase News and Research

RSS

Researchers identify biological process that appears to trigger Parkinson's disease

Working with human neurons and fruit flies, researchers at Johns Hopkins have identified and then shut down a biological process that appears to trigger a particular form of Parkinson's disease present in a large number of patients. A report on the study, in the April 10 issue of the journal Cell, could lead to new treatments for this disorder.

11 Apr 2014

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.

11 Apr 2014

Scientists discover potential cause of Parkinson’s disease

Researchers have discovered a process that appears to explain how a well known enzyme mutation triggers the neural deterioration seen in Parkinson’s disease.

10 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test.

10 Apr 2014

Research shows blocking DNA repair improves radiation therapy for glioblastomas

UT Southwestern Medical Center researchers have demonstrated in both cancer cell lines and in mice that blocking critical DNA repair mechanisms could improve the effectiveness of radiation therapy for highly fatal brain tumors called glioblastomas.

9 Apr 2014

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.

9 Apr 2014

Scientists uncover surprising link between brain development and gene tied to breast cancer

Scientists at the Salk Institute have uncovered details into a surprising-and crucial-link between brain development and a gene whose mutation is tied to breast and ovarian cancer.

9 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

Eli Lilly and Company will present early-stage data from several targeted cancer therapies – including bemaciclib "beh meh sye' klib" (LY2835219), its oral, cell-cycle inhibitor of CDK4/6 – that make up its diverse clinical oncology pipeline during the American Association for Cancer Research (AACR) Annual Meeting 2014 held in San Diego, Calif. from April 5 – 9.

7 Apr 2014

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.

7 Apr 2014

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

...

7 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

Too little or too much of SRPK1 enzyme promotes cancer, shows research

Researchers at the University of California, San Diego School of Medicine have found that too little or too much of an enzyme called SRPK1 promotes cancer by disrupting a regulatory event critical for many fundamental cellular processes, including proliferation.

4 Apr 2014

New therapeutic agent reduces age-related sleep problems in fruit flies

Elderly flies do not sleep well - they frequently wake up during the night and wander around restlessly. The same is true of humans. For researchers at the Max Planck Institute for Biology of Ageing in Cologne, the sleeplessness experienced by the fruit fly Drosophila is therefore a model case for human sleeping behaviour.

2 Apr 2014

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

The Lancet Oncology has published results from the largest ever trial of a single melanoma treatment. The open label safety study was conducted to assess the tolerability of Zelboraf (vemurafenib), and featured 3,222 patients from across 44 countries.1 246 of these patients were from the UK.

2 Apr 2014

Genetic variations influence risk for developing choline deficiency symptoms

What is now considered to be the "right" amount of the essential nutrient, choline, might actually be "wrong," depending on who you are. That's because scientists have found that the "right" amount of choline needed by an individual is influenced by a wide range of factors, including gender, life stage, race and ethnicity of the individual.

29 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Kinase News and Research

Researchers identify biological process that appears to trigger Parkinson's disease

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Scientists discover potential cause of Parkinson’s disease

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

Research shows blocking DNA repair improves radiation therapy for glioblastomas

Researchers identify experimental drugs to block treatment-resistant leukemia

Scientists uncover surprising link between brain development and gene tied to breast cancer

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Eli Lilly presents early-stage data from several targeted cancer therapies at AACR 2014

New insights provide novel therapeutic approach against cancer

Deciphera Pharmaceuticals initiates Phase 1 clinical trial of pan-RAF inhibitor LY3009120

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Too little or too much of SRPK1 enzyme promotes cancer, shows research

New therapeutic agent reduces age-related sleep problems in fruit flies

Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma

Genetic variations influence risk for developing choline deficiency symptoms

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News